Log in to your Inderes Free account to see all free content on this page.
ALK-Abelló
153.1 DKK +0.99%HC Andersen Capital receives payment from ALK-Abelló for a DigitalIR/Corporate Visibility agreement. See disclaimer.
10 investors are following this company
ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,900 people worldwide and is listed on Nasdaq Copenhagen.
Revenue
4.82B
EBIT %
13.81 %
P/E
69.59
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Copenhagen
ALK B
Daily low / high price
150.6 / 153.6
DKK
Market cap
34.11B DKK
Turnover
21.84M DKK
Volume
143K
Financial calendar
Interim report
23.08.2024
Interim report
14.11.2024
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
The Lundbeck Foundation | 40.3 % | 67.2 % |
The Danish Labour Market Supplementary Pension ( ATP) | 7.5 % | 4.1 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
ALK provides update on regulatory process for the house dust mite allergy tablet in China
ALK launches new growth strategy and 2028 financial ambitions
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio